IOVA - Iovance Biotherapeutics, Inc.
14.90 0.00 (0.00%)
After hours: 4:37PM EDT
| Previous Close | 14.65 |
| Open | 14.75 |
| Bid | 14.70 x 800 |
| Ask | 14.90 x 100 |
| Day's Range | 14.55 - 15.90 |
| 52 Week Range | 4.45 - 19.90 |
| Volume | 1,024,237 |
| Avg. Volume | 935,053 |
| Market Cap | 1.336B |
| Beta | 2.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.38 |
| Earnings Date | Jul 30, 2018 - Aug 3, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.33 |
- ACCESSWIRE•3 days ago
Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks
LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration. Gains were broad based as six out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: GlycoMimetics Inc. (NASDAQ: GLYC), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ).
- ACCESSWIRE•19 days ago
A Savvy Biotech Investor Is Betting Up To $25 Million Dollars On This $8 Stock Returning 250%... Or More?
Top-notch Great Point Partners is investing up to $25 million in Orgenesis' (ORGS) manufacturing subsidiary to enable global expansion. Company is already generating growing revenue, and this specialist healthcare fund investment substantiates the ORGS growth opportunity. Demand for CDMOs, like ORGS, is growing as more cell therapies (like gene therapies and CAR-T cells) come to market in the coming years.
- ACCESSWIRE•last month
Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar
Stock Research Monitor: JAGX, JAZZ, and LJPC LONDON, UK / ACCESSWIRE / June 15, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration . On Thursday, June 14, ...
- Zacks•last month
Iovance Biotherapeutics (IOVA) Jumps: Stock Rises 5.1%
Iovance Biotherapeutics (IOVA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- GlobeNewswire•last month
Iovance Biotherapeutics Announces First Patient Dosed in Europe for Ongoing C-144-01 Phase 2 Trials in Metastatic Melanoma
“The dosing of the first patient with lifileucel in Europe for the treatment of metastatic melanoma marks an important milestone for Iovance and our global development plans as our European Union (EU) manufacturing is now able to support enrollment in that region,” said Dr. Maria Fardis, PhD, MBA, president and chief executive officer of Iovance Biotherapeutics. In December 2017, the company announced that the Generation 2 manufacturing process, with a duration of 22 days, was selected and all studies were shifted to utilize that method of manufacturing. The company has manufacturing capability in both the US and EU. This is the first patient treated with TIL developed in an EU-based manufacturing facility.
- Simply Wall St.•last month
Iovance Biotherapeutics Inc (NASDAQ:IOVA): When Will It Breakeven?
Iovance Biotherapeutics Inc’s (NASDAQ:IOVA): Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicateRead More...
- Zacks•2 months ago
Implied Volatility Surging for Iovance Biotherapeutics (IOVA) Stock Options
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.
- GlobeNewswire•2 months ago
Iovance Biotherapeutics to Present at Two Investor Conferences in June
SAN CARLOS, Calif., May 31, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that ...
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind ServisFirst Bancshares, Iovance Biotherapeutics, Inc., MarineMax, TriNet Group, Dorian LPG, and AAON — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, May 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ServisFirst ...
- TheStreet.com•2 months ago
4 Small Speculative Names on My Radar
While I'm waiting for some index excitement I'm focused on trades in individual stocks.
- ACCESSWIRE•2 months ago
Blog Exposure - RXi Pharma and Iovance Biotherapeutics Announce Research Collaboration
LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on RXi Pharma Corp. (NASDAQ: RXII), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RXII as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it has inked a research collaboration deal with Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance") to evaluate the potential synergies with RXi's novel sd-rxRNA therapeutic compounds and Iovance's autologous cell therapy based on tumor-infiltrating lymphocytes (TILs), for use in the treatment of cancer.
- ACCESSWIRE•2 months ago
Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks
Under assessment are the following four stocks: Intrexon Corp. (NYSE: XON), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Germantown, Maryland-based Intrexon Corp.'s stock plummeted 19.64%, finishing last Friday's trading session at $14.98.
- Zacks Small Cap Research•2 months ago
RXII: Partner Relationships in TILs to Drive Future Value
RXi reported revenues of $23,000 for the quarter from grants related to BioAxone’s work in spinal cord injury, compared to zero in revenues in 1Q:17. Following the availability of the trial results, RXi will set up data rooms for interested buyers.
- Associated Press•2 months ago
Iovance Biotherapeutics: 1Q Earnings Snapshot
The San Carlos, California-based company said it had a loss of 31 cents per share. Losses, adjusted for stock option expense, came to 26 cents per share. The results beat Wall Street expectations. The ...
- GlobeNewswire•2 months ago
Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
-Company to Host Conference Call at 4:30pm ET Today-. SAN CARLOS, Calif., May 10, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating ...
- GlobeNewswire•3 months ago
Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018
SAN CARLOS, Calif., May 03, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that ...
- American City Business Journals•3 months ago
New HQ puts Tampa immunotherapy company in Moffitt’s backyard
Morphogenesis is part of the burgeoning life science sector that state and local economic development officials want to expand. It’s one of at least three companies establishing offices that are near Moffitt, a national leader in cancer treatment.
- GlobeNewswire•3 months ago
Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in May
SAN CARLOS, Calif., May 02, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that ...
- Associated Press•4 months ago
Iovance Biotherapeutics posts 4Q loss
On a per-share basis, the San Carlos, California-based company said it had a loss of 36 cents. Losses, adjusted for stock option expense, came to 32 cents per share. The results met Wall Street expectations. ...
- ACCESSWIRE•4 months ago
Iovance Biotherapeutics Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Iovance Biotherapeutics Inc (NASDAQ: IOVA ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018, at 4:30 PM Eastern ...
- PR Newswire•4 months ago
Johnson Fistel, LLP Announces Investigations of RH, WageWorks, Inc., BRF S.A., and Iovance Biotherapeutics, Inc.; Investors Encouraged to Contact Firm
SAN DIEGO , March 6, 2018 /PRNewswire/ --Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against RH, WageWorks, Inc., BRF S.A., and Iovance Biotherapeutics, Inc., as detailed ...
